MARKET

VNDA

VNDA

Vanda Pharma
NASDAQ
10.91
-0.05
-0.46%
After Hours: 10.91 0 0.00% 16:01 12/02 EST
OPEN
10.90
PREV CLOSE
10.96
HIGH
10.97
LOW
10.27
VOLUME
251.19K
TURNOVER
0
52 WEEK HIGH
18.00
52 WEEK LOW
9.24
MARKET CAP
617.40M
P/E (TTM)
97.58
1D
5D
1M
3M
1Y
5Y
BRIEF-Vanda Pharma Reports Results In Phase Ii Clinical Study Of Anxiety Drug
Reuters · 2d ago
Vanda Pharmaceuticals Reports Results In A Phase II Clinical Study Of VQW-765 In The Treatment Of Acute Performance Anxiety
Benzinga · 2d ago
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2022:
PR Newswire · 11/09 01:30
Vanda Pharmaceuticals is spending big on R&D. Here’s what it has on tap for 2023.
Vanda Pharmaceuticals Inc. has successfully brought to market drugs for schizophrenia and sleep disorders, and now it’s looking to new areas of treatment to drive its next phase of growth. The D.C. based biotech is advancing several clinical trials for tr...
American City Business Journals · 11/03 19:24
Vanda Pharmaceuticals GAAP EPS of $0.06, revenue of $65.32M
Seekingalpha · 11/02 20:50
BRIEF-Vanda Pharmaceuticals Reports Q3 2022 Financial Results
Reuters · 11/02 20:20
Vanda Pharmaceuticals Q3 EPS $0.06 Misses $0.09 Estimate, Sales $65.32M Miss $71.00M Estimate
Benzinga · 11/02 20:03
Vanda Pharmaceuticals Q3 EPS, Revenue Lower; Revises 2022 Guidance
Vanda Pharmaceuticals Q3 EPS, Revenue Lower; Revises 2022 Guidance
MT Newswires · 11/02 17:10
More
About VNDA
Vanda Pharmaceuticals Inc. (Vanda) is a global biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Vanda’s commercial portfolio comprised of two products, HETLIOZ and nighttime sleep disturbances, and Fanapt for the treatment of schizophrenia. In addition, the Company has a range of drugs in development, including HETLIOZ (tasimelteon) for the treatment of jet lag disorder, delayed sleep phase disorder (DSPD), symptoms of autism spectrum disorder and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson s disease psychosis and a long acting injectable formulation for the treatment of schizophrenia; Tradipitant (VLY-686) for the treatment of gastroparesis, motion sickness, atopic dermatitis, and Covid-19 pneumonia, and VTR-297 for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.

Webull offers kinds of Vanda Pharmaceuticals Inc. stock information, including NASDAQ:VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.